Peptide Reference Desk
Exenatide vs Semaglutide: exendin-4 lineage versus a human GLP-1 analogue
Exenatide and semaglutide activate GLP-1R, but their sequence lineages and formulation histories are different enough to require separate analytical methods.
Same receptor does not mean same scaffold
Exenatide is based on exendin-4, a 39-residue peptide first identified through Gila monster biology. Semaglutide is a modified human GLP-1 analogue with substitutions and a fatty-acid side chain. The shared GLP-1 receptor target is a pharmacology category, not a sequence relationship.
Why the chemistry matters
Semaglutide’s acylation and linker require attention to conjugate identity and related substances. Exenatide has a different sequence, degradation profile and product history. A generic “GLP-1 purity method” should not be assumed suitable for both.
Use head-to-head evidence carefully
When comparing trial outcomes, record formulation, population, comparator, duration and analysis method. When comparing research lots, use molecule-specific expected mass, peptide mapping, HPLC and content. Approved brand evidence does not qualify an unrelated research vial.
Verify with primary records
Use the primary paper, current regulator label or lot-linked analytical file for the claim it supports. A search result is a route to evidence, not the evidence itself.